Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src-mediated phosphorylation of EGF receptor tyrosine kinase

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 821-828

  Kundu, Juthika ^a   Choi, Bu Young ^b   Jeong, Chul Ho ^a   Kundu, Joydeb Kumar ^a   Chun, Kyung Soo ^a  

^a Keimyung University   (South Korea)

^b Seowon University   (South Korea)

Author keywords

Apoptosis; EGFR; HCT116 cells; STAT3; Thymoquinone

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CASPASE INHIBITOR; CYCLIN D1; CYCLIN D2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; JANUS KINASE 2; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PAN CASPASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SURVIVIN; THYMOQUINONE; TYROSINE; UNCLASSIFIED DRUG; Z VAD FMK; BENZOQUINONE DERIVATIVE; CSK TYROSINE-PROTEIN KINASE; EGFR PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE ACTIVITY; GENE INACTIVATION; GENE PRODUCT; HCT116 CELL LINE; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; CELL PROLIFERATION; COLON TUMOR; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

APOPTOSIS; BENZOQUINONES; CELL PROLIFERATION; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; JANUS KINASE 2; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84903178517     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3223     Document Type: Article

References (49)

1. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Merika E, Saif MW, Katz A, Syrigos K and Morse M: Review. Colon cancer vaccines: an update. In Vivo 24: 607-628, 2010.
4. Chung MY, Lim TG and Lee KW: Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development. World J Gastroenterol 19: 984-993, 2013.
5. Banerjee S, Padhye S, Azmi A, et al: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer 62: 938-946, 2010.
6. Kundu J, Kim DH, Kundu JK and Chun KS: Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets. Food Chem Toxicol 65: 18-26, 2014.
7. Kundu JK, Liu L, Shin JW and Surh YJ: Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo. Biochem Biophys Res Commun 438: 721-727, 2013.
8. Lei X, Lv X, Liu M, et al: Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun 417: 864-868, 2012.
9. Yi T, Cho SG, Yi Z, et al: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7: 1789-1796, 2008.
10. Gali-Muhtasib H, Diab-Assaf M, Boltze C, et al: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 25: 857-866, 2004.
11. Gali-Muhtasib H, Ocker M, Kuester D, et al: Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med 12: 330-342, 2008.
12. Jafri SH, Glass J, Shi R, Zhang S, Prince M and Kleiner-Hancock H: Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res 29: 87, 2010.
13. Kaseb AO, Chinnakannu K, Chen D, et al: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67: 7782-7788, 2007. (Pubitemid 47281372)
14. Jrah-Harzallah H, Ben-Hadj-Khalifa S, Almawi WY, Maaloul A, Houas Z and Mahjoub T: Effect of thymoquinone on 1,2-dimethylhydrazine- induced oxidative stress during initiation and promotion of colon carcinogenesis. Eur J Cancer 49: 1127-1135, 2013.
15. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
16. Burz C, Berindan-Neagoe I, Balacescu O and Irimie A: Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 48: 811-821, 2009.
17. Martin SJ and Green DR: Protease activation during apoptosis: death by a thousand cuts? Cell 82: 349-352, 1995.
18. Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol 13: 211-217, 2001.
19. Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL and Wolff RK: JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog 52: 155-166, 2013.
20. Laird AD, Li G, Moss KG, et al: Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2: 461-469, 2003.
21. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E and Smith PD: EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 19: 1155-1160, 2001.
22. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S and DiGiovanni J: Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 64: 2382-2389, 2004. (Pubitemid 38523890)
23. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171: 59-76, 2009.
24. Johnston PA and Grandis JR: STAT3 signaling: anticancer strategies and challenges. Mol Interv 11: 18-26, 2011.
25. Masuda M, Suzui M, Yasumatu R, et al: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
26. Dowlati A, Nethery D and Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 3: 459-463, 2004. (Pubitemid 39193723)
27. Kong L, Deng Z, Shen H and Zhang Y: Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem 348: 11-19, 2011.
28. Kopetz S: Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res 1: S37-S41, 2007.
29. Mann JR, Backlund MG and DuBois RN: Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2: 202-210, 2005. (Pubitemid 40812470)
30. Woo CC, Kumar AP, Sethi G and Tan KH: Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 83: 443-451, 2012.
31. El-Najjar N, Chatila M, Moukadem H, et al: Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15: 183-195, 2010.
32. Gali-Muhtasib H, Kuester D, Mawrin C, et al: Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 68: 5609-5618, 2008.
33. Koka PS, Mondal D, Schultz M, Abdel-Mageed AB and Agrawal KC: Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med 235: 751-760, 2010.
34. Hussain AR, Uddin S, Ahmed M, Al-Dayel F, Bavi PP and Al-Kuraya KS: Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PLoS One 8: e60540, 2013.
35. Valassiadou KE, Stefanaki K, Tzardi M, et al: Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 17: 2571-2576, 1997. (Pubitemid 27352655)
36. Bonnotte B, Favre N, Moutet M, et al: Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 161: 1433-1438, 1998. (Pubitemid 28380574)
37. Dobi E, Monnien F, Kim S, et al: Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 12: 28-36, 2013.
38. Corvinus FM, Orth C, Moriggl R, et al: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7: 545-555, 2005. (Pubitemid 40967755)
39. Lin Q, Lai R, Chirieac LR, et al: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005. (Pubitemid 41416250)
40. Badr G, Mohany M and Abu-Tarboush F: Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis 10: 236-243, 2011.
41. Li F, Rajendran P and Sethi G: Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol 161: 541-554, 2010.
42. Zhang X, Liu P, Zhang B, Mao H, Shen L and Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med 32: 623-628, 2013.
43. Kanda N, Seno H, Konda Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004. (Pubitemid 38932164)
44. Asanuma K, Tsuji N, Endoh T, Yagihashi A and Watanabe N: Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 172: 3922-3929, 2004. (Pubitemid 38337980)
45. Lin L, Liu A, Peng Z, et al: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 71: 7226-7237, 2011.
46. Forgue-Lafitte ME, Coudray AM, Breant B and Mester J: Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene. Cancer Res 49: 6566-6571, 1989. (Pubitemid 20008788)
47. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19, 2008.
48. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R and Omidi Y: Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev 13: 4751-4756, 2012.
49. Boehm AL, Sen M, Seethala R, et al: Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73: 1632-1642, 2008. (Pubitemid 351724352)